Sacha Gnjatic

Q: What Schools Are Affiliated With Sacha Gnjatic

Sacha Gnjatic is affiliated with the following schools: University of Lausanne, MD Anderson Cancer Center, University of Oxford, Université Paris Cité, Istanbul University, Weill Cornell Medicine, Icahn School of Medicine at Mount Sinai, Cornell University, Okayama University, Tokyo Medical University, Technical University of Munich, Paris Diderot University

Sacha Gnjatic's AcademicInfluence.com Rankings

Sacha Gnjatic

Medical

#3427

World Rank

#3895

Historical Rank

Oncology

#240

World Rank

#248

Historical Rank

medical Degrees

Sacha Gnjatic

Biology

#13487

World Rank

#17032

Historical Rank

Immunology

#931

World Rank

#955

Historical Rank

biology Degrees

Download Badge

Medical
Biology

Sacha Gnjatic's Degrees

PhD Immunology Université Paris Cité
Doctorate Medicine Université Paris Cité

Why Is Sacha Gnjatic Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Sacha Gnjatic's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. (2005) (2181)
Immunologic correlates of the abscopal effect in a patient with melanoma. (2012) (1745)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (1522)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. (2008) (893)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses (2017) (791)
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. (2016) (734)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer (2017) (720)
Cancer classification using the Immunoscore: a worldwide task force (2012) (719)
Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (686)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade (2018) (497)
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma (2007) (464)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. (2004) (460)
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. (2014) (458)
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. (2000) (455)
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. (2000) (420)
Single-cell immune landscape of human atherosclerotic plaques (2019) (376)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors (2021) (364)
Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. (2011) (361)
The abscopal effect associated with a systemic anti-melanoma immune response. (2013) (361)
Classification of current anticancer immunotherapies (2014) (357)
CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens (2008) (338)
NY-ESO-1: review of an immunogenic tumor antigen. (2006) (336)
Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non–Small Cell Lung Cancer (2005) (336)
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit (2008) (335)
Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy (2018) (324)
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab (2011) (323)
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) (2020) (258)
Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer (2007) (255)
Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) (2020) (252)
Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma (2000) (249)
NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. (2003) (243)
Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1 (2008) (237)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients (2012) (237)
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses (2003) (230)
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients (2006) (218)
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses. (2008) (208)
Pathophysiology of SARS-CoV-2: targeting of endothelial cells renders a complex disease with thrombotic microangiopathy and aberrant immune response. The Mount Sinai COVID-19 autopsy experience (2020) (200)
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. (2005) (186)
Vaccine-Induced CD4+ T Cell Responses to MAGE-3 Protein in Lung Cancer Patients1 (2004) (183)
Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 (2000) (180)
The non-small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome. (2015) (177)
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy (2017) (175)
Seromic profiling of ovarian and pancreatic cancer (2010) (174)
Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients (2012) (173)
In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. (2006) (168)
Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. (2007) (164)
Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer (2014) (157)
Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming (2008) (156)
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma (2013) (150)
Ipilimumab for patients with advanced mucosal melanoma. (2013) (140)
Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience (2021) (136)
Toll-Like Receptor Agonists: Are They Good Adjuvants? (2010) (136)
Host tissue determinants of tumour immunity (2019) (135)
Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. (1998) (131)
In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide (2016) (123)
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity (2015) (120)
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. (2000) (120)
Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM)--correlation with prognostic factors. (2007) (119)
Consensus nomenclature for CD8+ T cell phenotypes in cancer (2015) (118)
Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma (2012) (115)
Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival (2009) (112)
Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity (2011) (106)
Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City (2020) (102)
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients (2013) (101)
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation (2020) (101)
Covid-19 and People with HIV Infection: Outcomes for Hospitalized Patients in New York City. (2020) (99)
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. (2017) (94)
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations (2002) (94)
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. (2002) (93)
Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms (2021) (92)
Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission (2008) (92)
NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors (2004) (90)
CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients (2002) (89)
Chemoradiotherapy-induced upregulation of PD-1 antagonizes immunity to HPV-related oropharyngeal cancer. (2014) (88)
An inflammatory cytokine signature helps predict COVID-19 severity and death (2020) (86)
PLAC1, a trophoblast-specific cell surface protein, is expressed in a range of human tumors and elicits spontaneous antibody responses. (2007) (83)
Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. (2009) (81)
NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer (2012) (79)
Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments (2004) (78)
Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. (2008) (77)
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. (2003) (74)
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. (2012) (74)
Direct tumor recognition by a human CD4+ T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses (2015) (73)
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells (2009) (73)
Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity (2012) (72)
Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma (2015) (72)
Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging (2017) (70)
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward (2020) (69)
The Spontaneous CD8+ T-Cell Response to HLA-A2-Restricted NY-ESO-1b Peptide in Hepatocellular Carcinoma Patients (2004) (68)
NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer (2004) (68)
Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies (2021) (67)
Cross-Presentation of HLA Class I Epitopes from Exogenous NY-ESO-1 Polypeptides by Nonprofessional APCs 1 (2003) (65)
MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma (2020) (63)
Expression and Immune Responses to MAGE Antigens Predict Survival in Epithelial Ovarian Cancer (2014) (63)
Prostate Cancer Progression Correlates with Increased Humoral Immune Response to a Human Endogenous Retrovirus GAG Protein (2013) (62)
Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. (2003) (60)
Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination1 (2006) (60)
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward (2020) (58)
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. (2003) (56)
Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial (2013) (55)
Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). (2006) (55)
Serological response to mRNA COVID-19 vaccines in IBD patients receiving biological therapies (2021) (55)
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1 (2019) (54)
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. (2007) (54)
Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF (2008) (53)
NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer (2010) (52)
MAGE-A3 is highly expressed in a subset of colorectal cancer patients. (2012) (51)
Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas (2010) (51)
Improving the efficacy of cancer immunotherapy. (2009) (50)
Autoantibodies against cancer antigens. (2009) (50)
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity (2022) (49)
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. (2010) (48)
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. (2017) (47)
A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF. (2016) (47)
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma (2021) (46)
Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. (2012) (45)
Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma (2019) (45)
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope (2016) (45)
Trypanosoma cruzi as an effective cancer antigen delivery vector (2011) (45)
Nonclassical Antigen-Processing Pathways Are Required for MHC Class II–Restricted Direct Tumor Recognition by NY-ESO-1–Specific CD4+ T Cells (2013) (44)
Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. (2010) (43)
In vitro Stimulation of CD8 and CD4 T Cells by Dendritic Cells Loaded with a Complex of Cholesterol-Bearing Hydrophobized Pullulan and NY-ESO-1 Protein: Identification of a New HLA-DR15–Binding CD4 T-Cell Epitope (2006) (43)
Clinical Trial of the Intratumoral Administration of Labeled DC Combined With Systemic Chemotherapy for Esophageal Cancer (2012) (42)
Immunization With a Recombinant MAGE-A3 Protein After High-dose Therapy for Myeloma (2007) (41)
Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer. (2004) (40)
Expression of cancer testis antigen CT45 in classical Hodgkin lymphoma and other B-cell lymphomas (2010) (40)
NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus (2015) (39)
Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules (1995) (39)
IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. (2004) (39)
Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. (2002) (39)
Gastrointestinal involvement attenuates COVID-19 severity and mortality (2020) (39)
Spatial CRISPR genomics identifies regulators of the tumor microenvironment (2022) (37)
Characterization of Preexisting MAGE-A3-Specific CD4+ T Cells in Cancer Patients and Healthy Individuals and Their Activation by Protein Vaccination1 (2009) (35)
First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient (2017) (35)
Heteroclitic serological response in esophageal and prostate cancer patients after NY‐ESO‐1 protein vaccination (2012) (35)
Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. (2016) (34)
Heat Shock Protein 90-Mediated Peptide-Selective Presentation of Cytosolic Tumor Antigen for Direct Recognition of Tumors by CD4+ T Cells (2012) (33)
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. (2008) (33)
Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer. (2004) (33)
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children (2021) (33)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Ex-Vivo Analysis of CD8+ T Cells Infiltrating Colorectal Tumors Identifies a Major Effector-Memory Subset with Low Perforin Content (2006) (30)
Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. (2022) (30)
Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma (2019) (29)
Tumor‐reactive CD8+ T‐cell clones in patients after NY‐ESO‐1 peptide vaccination (2007) (28)
Multiplexed Immunohistochemical Consecutive Staining on Single Slide (MICSSS): Multiplexed Chromogenic IHC Assay for High-Dimensional Tissue Analysis. (2019) (27)
negatively regulated by LAG-3 and PD-1 in human ovarian cancer (2010) (27)
Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis (2019) (26)
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1 (2008) (25)
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer (2021) (24)
Immunotherapy biomarkers 2016: overcoming the barriers (2017) (24)
32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2017): Part One (2017) (22)
First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1 (2019) (21)
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas (2015) (21)
A novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapy. (2013) (21)
Sampling the host response to SARS-CoV-2 in hospitals under siege (2020) (21)
MAGE expression in head and neck squamous cell carcinoma primary tumors, lymph node metastases and respective recurrences-implications for immunotherapy (2017) (20)
Therapeutic administration of a synthetic CpG oligodeoxynucleotide triggers formation of anti-CpG antibodies. (2012) (20)
Immunohistochemical Detection of γ/δ T Lymphocytes in Formalin-fixed Paraffin-embedded Tissues (2019) (20)
Spatial positioning and matrix programs of cancer-associated fibroblasts promote T cell exclusion in human lung tumors (2022) (20)
BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology (2020) (19)
SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art (2018) (18)
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS). (2017) (18)
Cancer/testis antigens expression and autologous serological response in a set of Brazilian non-Hodgkin’s lymphoma patients (2012) (17)
A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID‐19 (2021) (17)
Expression and clinical significance of MAGE and NY‐ESO‐1 cancer‐testis antigens in adenoid cystic carcinoma of the head and neck (2016) (17)
Inducing Efficient Cross-priming Using Antigen-coated Yeast Particles (2008) (16)
Evaluation of LAGE-1 and NY-ESO-1 expression in multiple myeloma patients to explore possible benefits of their homology for immunotherapy. (2011) (16)
Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative (2022) (15)
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones. (2004) (14)
A multimodal imaging workflow to visualize metal mixtures in the human placenta and explore colocalization with biological response markers. (2016) (14)
Split T Cell Tolerance against a Self/Tumor Antigen: Spontaneous CD4+ but Not CD8+ T Cell Responses against p53 in Cancer Patients and Healthy Donors (2011) (14)
Monitoring CD 8 T cell responses to NY-ESO-1 : correlation of humoral and cellular immune responses (2017) (13)
Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing (2020) (13)
Melanoma and immunotherapy bridge 2015 (2016) (13)
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation (2021) (13)
Cytotoxic lymphocytes are dysregulated in multisystem inflammatory syndrome in children (2020) (12)
Overcoming regulatory T‐cell suppression by a lyophilized preparation of Streptococcus pyogenes (2013) (12)
Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR (2022) (12)
Phase I, first-in-human trial of LV305 in patients with advanced or metastatic cancer expressing NY-ESO-1. (2015) (12)
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 (2020) (12)
Identification of new NY‐ESO‐1 epitopes recognized by CD4+ T cells and presented by HLA‐DQ B1 03011 (2006) (12)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma (2021) (11)
A Streamlined CyTOF Workflow To Facilitate Standardized Multi-Site Immune Profiling of COVID-19 Patients (2020) (11)
Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine–Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma (2019) (10)
Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages (2020) (10)
Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer (2020) (10)
Urine antibody against human cancer antigen NY-ESO-1. (2002) (10)
A shift in lung macrophage composition is associated with COVID-19 severity and recovery (2022) (10)
Divergent early antibody responses define COVID-19 disease trajectories (2021) (10)
Serological response to COVID-19 vaccination in IBD patients receiving biologics (2021) (9)
Myeloid Cell–associated Resistance to PD-1/PD-L1 Blockade in Urothelial Cancer Revealed Through Bulk and Single-cell RNA Sequencing (2021) (9)
First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient. (2017) (9)
Cancer Immunotherapy: From local to global. (2017) (9)
Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery (2022) (8)
Initial reporting from the prospective National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS). (2021) (8)
Cancer-testis antigen expression and immunogenicity in AL amyloidosis (2012) (8)
Antigen depots: T cell traps? (2013) (8)
MAGE-A 3 is highly expressed in a subset of colorectal cancer patients (2011) (8)
Abstract LB-095: HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer enhances HPV-specific T cell immunity (2016) (8)
Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates (2014) (8)
Impact of gemcitabine + cisplatin + ipilimumab on circulating immune cells in patients (pts) with metastatic urothelial cancer (mUC). (2015) (8)
A COMMON PITUITARY AUTOANTIBODY IN TWO PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR-MEDIATED HYPOPHYSITIS: ZCCHC8. (2020) (7)
MAGE-A3 Recombinant Protein (recMAGE-A3) Immunotherapy and Autologous Peripheral Blood Lymphocyte (PBL) Infusion Is Safe and Induces Robust Humoral Immune Responses In Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (autoSCT) (2013) (7)
Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy (2021) (7)
Multiplex Tissue Imaging Harmonization: A Multicenter Experience from CIMAC-CIDC Immuno-Oncology Biomarkers Network (2021) (7)
Single-agent LV305 to induce anti-tumor immune and clinical responses in patients with advanced or metastatic sarcoma and other cancers expressing NY-ESO-1. (2016) (7)
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. (2016) (7)
Neutralizing anti-GM-CSF autoantibodies recognize posttranslational glycosylations on GM-CSF years prior to diagnosis and predict complicated Crohn's Disease. (2022) (6)
Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer (2012) (6)
A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers. (2017) (6)
A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. (2018) (6)
Cancer–Testis Antigen 7 Expression and Immune Responses Following Allogeneic Stem Cell Transplantation for Multiple Myeloma (2014) (6)
Split T-cell tolerance as a guide for the development of tumor antigen-specific immunotherapy (2012) (6)
Phase I study of PD-L1 inhibition with avelumab and laser interstitial thermal therapy in patients with recurrent glioblastoma. (2019) (6)
Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages. (2020) (6)
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges (2020) (6)
DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC). (2017) (5)
Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies (2021) (5)
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae (2022) (5)
Abstract B109: In-depth tissue analysis using multiplexed immunohistochemical consecutive staining on single slide (2016) (5)
Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients. (2017) (5)
Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae (2022) (5)
Circulating proteins to predict adverse COVID-19 outcomes (2021) (5)
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) (2021) (4)
Fatal breakthrough infection after anti-BCMA CAR-T therapy highlights suboptimal immune response to SARS-CoV-2 vaccination in myeloma patients (2021) (4)
Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2 (2016) (4)
Erratum: Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans (Proceedings of the National Academy of Sciences of the United States of America (July 20, 2004) 101, 29 (10697-10702)) (2005) (4)
Perturb-map enables CRISPR genomics with spatial resolution and identifies regulators of tumor immune composition (2021) (4)
Recombinant (rec) MAGE-A3 Protein Immunotherapy and Peripheral Blood Lymphocyte (PBL) Reconstitution Induce Strong Antigen-Specific Humoral and Cellular Immune Responses in Patients Undergoing Autologous Stem Cell Transplantation (ASCT) for Consolidation of Multiple Myeloma (MM) (2014) (4)
Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC (2021) (3)
Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (3)
A phase 1 clinical trial of NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM® adjuvant) in patients with minimal residual disease (2003) (3)
Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma (2021) (3)
A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients in complete clinical remission. (2019) (3)
Cancer vaccines (2022) (3)
Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study (2020) (3)
Vaccination with MAGE-3 Protein Can Induce a Potent Immune Response in a Healthy Donor Which Can Be Adoptively Transferred Via Stem Cell Transplant (Tx) to a Multiple Myeloma (MM) Patient. (2005) (3)
Autoimmunity in Down’s syndrome via cytokines, CD4 T cells and CD11c+ B cells (2023) (3)
Application of a 27-protein candidate cardiovascular surrogate endpoint to track risk ascendancy and resolution in COVID-19. (2021) (3)
Impact of chemotherapy alone, and chemotherapy plus ipilimumab, on circulating immune cells in patients with metastatic bladder cancer (2015) (2)
Intratumoral mregDC and CXCL13 T helper niches enable local differentiation of CD8 T cells following PD-1 blockade (2022) (2)
Abstract B015: Expansion and activation of CD103+dendritic cell progenitors at the tumor site transform tumor response to PD-L1 and BRAF inhibition (2016) (2)
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. (2023) (2)
The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals (2022) (2)
Th 1 / Th 2 CD 4 + T cell responses against NY-ESO-1 in HLA-DPB 1 * 0401 / 0402 patients with epithelial ovarian cancer (2004) (2)
Intratumoral checkpoint subversion as a strategy for minimizing adverse effects (2014) (2)
Integrated Cytof, Scrna-Seq and Cite-Seq Analysis of Bone Marrow Immune Microenvironment in the Mmrf Commpass Study (2020) (2)
Acute COVID-19 gene-expression profiles show multiple etiologies of long-term sequelae (2021) (2)
Phase I/II study of resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma. (2012) (2)
Booster vaccination of non-small cell lung cancer (NSCLC) patients with MAGEA3 protein and AS02B adjuvant (2007) (2)
A case of spontaneous systemic immunity to melanoma associated with cure after amputation for extensive regional recurrence (2013) (2)
Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges (2020) (2)
Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege (2020) (2)
Immunogenic Targets in Non–Small Cell Lung Cancer: More Is More (2005) (2)
Immune Profiling of Atherosclerotic Plaques Identifies Innate and Adaptive Dysregulations Associated with Ischemic Cerebrovascular Events (2019) (2)
The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals (2022) (2)
400 GM-CSF AUTOANTIBODIES PRECEDE THE DEVELOPMENT OF CROHN'S DISEASE AND PREDICT COMPLICATED PHENOTYPE AT DIAGNOSIS (2020) (2)
Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma (2021) (2)
Cellular immune responses against CT 7 ( MAGE-C 1 ) and humoral responses against other cancer-testis antigens in multiple myeloma patients (2005) (2)
LUD00-014: Phase I Study of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in patients with NY-ESO-1 or LAGE positive cancers (2004) (2)
A first-in-human phase 1 dose-escalating trial of G305 in patients with solid tumors expressing NY-ESO-1. (2015) (2)
Phase I/II study of the TLR3 agonist poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 vg in patients with melanoma. (2014) (2)
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma (2023) (2)
CD8+ tumor-infiltrating lymphocytes as a statistically significant marker of disease recurrence and survival in transitional cell carcinoma patients. (2006) (2)
Window of opportunity trial of HPV E7 antigen-expressing Listeria-based therapeutic vaccination prior to robotic surgery for HPV-positive oropharyngeal cancer. (2015) (2)
Immunization of ovarian cancer patients with an NY-ESO-1 peptide of dual MHC class I and II specificities plus incomplete Freund adjuvant induces simultaneous humoral, CD4+ and CD8+ T-cell responses (2005) (2)
Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma (2013) (2)
Immunogenicity of NY-ESO-1 cancer testis antigen in triple-negative breast cancer. (2012) (1)
629 Neoadjuvant nivolumab combined with CCR2/5 inhibitor or anti-IL-8 antibody in non-small cell lung cancer and hepatocellular carcinoma (2022) (1)
Tumor-reactive CD8 1 T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide V (2010) (1)
T1635 Expression of the Cancer Testis Antigen IGF2BP3 (IMP3) in Colorectal Cancers; IMP3 Holds Promise as a Specific Immunotherapy Target (2010) (1)
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists for resected stage IIB-IV melanoma. (2018) (1)
Characterization of T-Cell Exhaustion in Rapid Progressing Multiple Myeloma Using Cross Center Scrna-Seq Study (2021) (1)
Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege (2021) (1)
CIMAC-CIDC tissue imaging harmonization. (2020) (1)
A phase I study of NY-ESO-1 overlapping peptides with or without incomplete Freund's adjuvant and poly-ICLCL vaccination of ovarian cancer patients in second or third clinical remission. (2010) (1)
Abstract CT108: Immunogenicity of Poly-ICLC matured dendritic cells as an adjuvant for NY-ESO-1 and Melan-A-MART-1 peptide vaccination compared to Montanide® ISA-51 VG, in study subjects with melanoma in complete clinical remission but at high risk of disease recurrence (2022) (1)
Imiquimod: A TLR-7 agonist as adjuvant for a recombinant protein cancer vaccine (2007) (1)
A multiplexed immunohistochemical consecutive staining on single slide (MICSSS) analysis of the immune microenvironment of bile duct cancers (BDC) pre and post neoadjuvantchemotherapy (NACT). (2022) (1)
Cancer classification using the Immunoscore: a worldwide task force (2012) (1)
CIMAC-CIDC CyTOF harmonization. (2020) (1)
Protein and DNA-Based Vaccines With the NY-ESO-1 Antigen in Cancer Patients (2005) (1)
Abstract 5639: Changes in local and peripheral T cell diversity after HPV E7 antigen-expressing Listeria-based immunotherapy (ADXS11-001) prior to robotic surgery for HPV-positive oropharyngeal cancer (2018) (1)
Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001) (2021) (1)
CD3 and CD20 immune cell densities in primary tumors, lymph node metastasis, and recurrent disease samples of head and neck squamous cell carcinoma. (2020) (1)
Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis (2022) (1)
A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166. (2020) (1)
Immune response, safety, and overall survival of NY-ESO-1+ soft tissue sarcoma patients treated with CMB305 therapy. (2018) (1)
Abstract CT231: Clinical study of the safety and tolerability of laser interstitial thermal therapy and avelumab for recurrent glioblastoma (2020) (1)
IgG memory B cells expressing IL4R and FCER2 are associated with atopic diseases (2022) (1)
MAGE-A3 or NY-ESO1 Expression and Spontaneous Antibody Responses to NY-ESO1 in Newly Diagnosed Multiple Myeloma Patients Are Associated with Worse Overall Survival (2008) (1)
Benign Breast Tumors NY-ESO-1 Expression and Immunogenicity in Malignant and Updated (2004) (1)
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment (2021) (1)
Host Immune Responses Against CT Antigens in Multiple Myeloma Patients. (2006) (1)
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4 (cid:1) and CD8 (cid:1) T cell responses in humans (2004) (1)
Quantitative chest CT combined with plasma cytokines predict outcomes in COVID-19 patients (2021) (1)
An inflammatory cytokine signature predicts COVID-19 severity and survival (2020) (0)
Cancer Immunity 3 Suppl 1:15 (2003)-MEETING ABSTRACT (2003) (0)
Abstract 5325: Inhibition of CD4+CD25+ regulatory T cell suppression to anti-tumor responses by OK-432 (lyophilized Streptococcus pyogenes) (2010) (0)
Melanomas Epitope Presented by Breast Carcinomas and Recognition by Human CTL of a Wild-Type p53 Accumulation of the p53 Protein Allows (1997) (0)
Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 (2016) (0)
CTIM-09. PHASE I STUDY OF PD-L1 INHIBITION WITH AVELUMAB AND LASER INTERSTITIAL THERMAL THERAPY IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2021) (0)
Activation by Protein Vaccination Patients and Healthy Individuals and Their T Cells in Cancer + MAGE-A3-Specific CD4 Characterization of Preexisting (2009) (0)
Tumor-Reactive CTL Analogues Capable of Improved Stimulation Identification of NY-ESO-1 Peptide and Vincenzo (2000) (0)
NY-ESO-1 is associated with an aggressive phenotype of ovarian cancer (2017) (0)
Tumor immunity and immunosurveillance (PP-093) (2010) (0)
New dimensions in serology (2008) (0)
SOX2 antibody responses in patients with various tumor types and SCLC with and without paraneoplastic neurologic syndromes. (2006) (0)
Tumor-infiltrating T lymphocyte clonality predicts prognosis in human ovarian cancer (2013) (0)
Radiotherapy induces responses of lung cancer to CTLA-4 blockade (2018) (0)
Anti-integrin αvβ6 autoantibodies are a novel biomarker that antedate ulcerative colitis. (2023) (0)
EP1.04-15 NSCLC Response Determinants to Chemoimmunotherapy: Deep Profiling of Tumors Following Neoadjuvant Cemiplimab and Chemotherapy (2019) (0)
Abstract 5026: Dynamic changes in circulating protein levels reveal an association between ipilimumab and nivolumab combination treatment (SWOG Lung-MAP S1400I trial) with outcomes in squamous cell lung cancer (2022) (0)
Nonprofessional APCs from Exogenous NY-ESO-1 Polypeptides by Cross-Presentation of HLA Class I Epitopes (2003) (0)
Abstract 1729: Single-cell transcriptome profiling of multiple myeloma bone marrow samples suggests that disease progression interplays with tumor and tumor microenvironment in The MMRF CoMMpass Study (2022) (0)
289 PGV-001: a phase 1 trial of a personalized neoantigen peptide vaccine for the treatment of malignancies in the adjuvant setting (2020) (0)
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission (2023) (0)
Webinar | Immune response monitoring: What can we learn about immunotherapy, pathogen response, and autoimmunity? (2016) (0)
THE ROLE OF GROUP 3 INNATE LYMPHOID CELLS (ILC3) IN GM-CSF/CSF2RB-DEPENDENT INTESTINAL HOMEOSTASIS IN CROHN’S DISEASE (2022) (0)
Abstract A092: Comprehensive multidimensional analysis of the immune contexture in non-small cell lung cancer (2016) (0)
Cancer Immunity 3:19 (2003)-ARTICLE (2003) (0)
Abstract 2178: Circulating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab (2023) (0)
A Phase I Trial of VEGF-A Inhibition Combined with PD-L1 Blockade for Recurrent Glioblastoma (2023) (0)
Abstract LB-116: Strong MAGE-A3-specific humoral and cellular immune responses in multiple myeloma patients receiving MAGE-A3 protein immunotherapy and peripheral blood lymphocyte reconstitution (2015) (0)
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
Author Correction: Sampling the host response to SARS-CoV-2 in hospitals under siege (2021) (0)
Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy (2022) (0)
1 Long-term Complete Remission following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunological Correlates (2008) (0)
1477 First efficacy and multi-omic analysis data from phase 1 clinical trial of oncolytic viral immunotherapy with CAN-2409 + valacyclovir in combination with nivolumab and standard of care in newly diagnosed high-grade glioma (2022) (0)
A Stepwise Approach to the Development of Cancer Vaccines (2012) (0)
Abstract CT205: A phase I/Ib trial of intratumoral Poly-ICLC in resectable malignant pleural mesothelioma (2022) (0)
Phase I safety and immunogenicity study of NY-ESO-1b peptide and Montanide ISA-51 vaccination of patients with ovarian cancer (OC) in high risk first remission. (2006) (0)
Scientific category: Immunobiology Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma (2016) (0)
Anti-integrin αvβ6 autoantibodies are a novel predictive biomarker in ulcerative colitis (2022) (0)
Butanol Purified Food Allergy Herbal Formula-2 Has an Immunomodulating Effect ex-vivo in Pediatric Crohn's Disease Subjects (2021) (0)
Genetic engineering of T cells with receptors from NY-ESO-1-specific tumor-recognizing CD4+ T cell as a novel approach for adoptive T cell therapy (2015) (0)
Fr492 SIGNIFICANTLY REDUCED MORTALITY IN COVID-19 PATIENTS WITH GASTROINTESTINAL MANIFESTATIONS (2021) (0)
Host tissue determinants of tumour immunity (2019) (0)
595 Flt3L-primedin situvaccination and pembrolizumab induce systemic tumor regressions of bulky tumors in patients with lymphomas and ER/PR+ breast cancer (2022) (0)
Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib (2022) (0)
Prognostic effects of peripheral and tumor-infiltrating T-cell repertoire diversity in ovarian cancer. (2016) (0)
Abstract 4558: Mapping tolerized T cell states to exhaustion phenotypes in NSCLC (2019) (0)
Abstract 3381: Identifying tumor antigen-specific CD4+ T cell dysfunctional states by single cell transcriptomics in immunotherapy-treated cancer patients (2020) (0)
Abstract IA34: Mapping immune recognition of non-self neoantigens in human pancreatic cancer (2019) (0)
IMMU-60. MAPPING TUMORAL AND IMMUNE HETEROGENEITY IN PD-1 RESPONSIVE GLIOBLASTOMA (2018) (0)
Adjuvant Using TLR 7 Agonist Imiquimod as Vaccine Patients with Full-Length NY-ESO-1 Protein Immunization of Malignant Melanoma (2008) (0)
Abstract CT199: Rescuing response to ICI by blocking the type-2 immune axis in patients with NSCLC progressing on immunotherapy: A phase 1b/2 trial of dupilumab administered with checkpoint blockade (2023) (0)
HLA-DP 4 expression and immunity to NY-ESO-1 : correlation and characterization of cytotoxic CD 4 + CD 25-CD 8-T cell clones (2004) (0)
Recombinant MAGE-A3 protein immunotherapy and peripheral blood lymphocyte (PBL) reconstitution induce strong antigen-specific humoral and cellular immune responses in patients undergoing autologous stem cell transplantation (ASCT) for consolidation of multiple myeloma (MM) (2015) (0)
Antitumor immunity as the basis for durable disease-free, treatment-free survival (DDFTFS) in patients with metastatic urothelial cancer (mUC). (2023) (0)
CT7/MAGE-C1 Expression and Immune Responses Following Allogeneic Transplant for Multiple Myeloma (2013) (0)
Abstract PO-140: Unsupervised clustering and data modeling reveals molecular signatures linked a distinct African American enriched cluster with higher probability of death in triple negative breast cancer (2022) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
Cancer Immunity (12 July 2007) Vol. 7, p. 11 (2005) (0)
MAGE-3 Protein in Lung Cancer Patients Vaccine-Induced CD4+ T Cell Responses to (2013) (0)
P-074: Exploring batch effect in single-cell data integration in a multi-center multiple myeloma immune atlas initiative (2022) (0)
Vaccination With MAGE-3 Protein Induces A Potent Immune Response in A Healthy Donor Which Can Be Adoptively Transferred to A Multiple Myeloma Patient and Boosted by Further Vaccination (2005) (0)
Pilot study of MAGE-A3 protein vaccination and autologous stem cell transplantation (autoSCT) as consolidation therapy for multiple myeloma (MM). (2012) (0)
Immunological Effects and Clinical Activity Toxins) in Patients with NY-ESO-1 Expressing Cancers: Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's (2012) (0)
Proteomic Characterization of Acute Kidney Injury in Patients Hospitalized with SARS-CoV2 Infection (2023) (0)
Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy (2019) (0)
543 Response to checkpoint blockade in HCC is associated with IgG1 skewing (2022) (0)
Multi-Center Immune Profiling Mass Cytometry Assay Harmonization. (2021) (0)
Microenvironment and Immunology Transcription Factor NFATc 2 Controls the Emergence of Colon Cancer Associated with IL-6 – Dependent Colitis (2012) (0)
Correction: The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals (2022) (0)
Circulating proteins to predict COVID-19 severity. (2023) (0)
Abstract 1318: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma multiforme (2018) (0)
Single-Cell RNA-Seq Analysis of CD138-Depleted Bone Marrow Samples Reveals Genetic Alterations and Disease Progression Correlate with Tumor and Bone Marrow Immune Microenvironment in the Mmrf Commpass Study (2021) (0)
High Dimensional Immune Profiling in Smoldering Multiple Myeloma Identifies Novel Organizing Features of the Tumor Microenvironment (2019) (0)
Neutralizing Anti-Granulocyte Macrophage-Colony Stimulating Factor Autoantibodies Recognize Post-Translational Glycosylations on Granulocyte Macrophage-Colony Stimulating Factor Years Before Diagnosis and Predict Complicated Crohn’s Disease (2022) (0)
510. Elevated IL-1β level as a predictor of inflammation and death in COVID-19 (2020) (0)
P1.17-14 Prognostic Value of Immune Cell Biomarkers in Surgically Resectable Non-Small Cell Lung Cancer: A Meta-Analysis (2019) (0)
688 Prediction of HCC response to neoadjuvant immunotherapy using multiparametric magnetic resonance imaging: a preliminary study (2022) (0)
Peptide Vaccination T Cells following + on Low/High-Avidity CD4 Regulatory T Cells + CD25+ Influence of CD4 (2006) (0)
Broad Antigen Specificity T Cell Responses + and CD 4 + Human CD 8 Receptor or DEC-205 In Vitro Elicits Dual Antibody-Targeted NY-ESO-1 to Mannose (2010) (0)
Targets for Passive Immunotherapy Intracellular Tumor-Associated Antigens Represent Effective (2012) (0)
Reduced Antigen Presentation May Contribute to Immunomodulatory Drug Resistance in Multiple Myeloma (2019) (0)
Phase II Evaluation of an Allogeneic Tumor Cell Lysate Vaccine with or without Metronomic Oral Cyclophosphamide and Celecoxib in Patients with Thoracic Malignancies (2017) (0)
Architecture of Sample Preparation and Data Governance of Immuno-Genomic Data Collected from Bone Marrow and Peripheral Blood Samples Obtained from Multiple Myeloma Patients (2020) (0)
Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging (2017) (0)
Phase 1 Study of Elotuzumab and Peripheral Blood Mononuclear Cell Reconstitution in Combination with Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma (2017) (0)
Abstract CT270: Immunogenicity of PGV_001 neoantigen vaccine in a Phase-I clinical trial, across various types of cancers in adjuvant setting (2023) (0)
Abstract B062: Differences of transcriptional profiles between long-term tolerized and memory CD4 T cells (2016) (0)
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer (2021) (0)
A methylation clock model of mild SARS-CoV-2 infection provides insight into immune dysregulation. (2023) (0)
Abstract IA31: Measuring the emergence of non-self in tumors (2019) (0)
Abstract 1229: Pre-existing NY-ESO-1-specific T cell reactivity is associated with improved clinical outcome in castration resistant prostate cancer patients treated with Prostate GVAX and ipilimumab. (2013) (0)
Identification and Validation of CD138- Multiple Myeloma Immune and Tumor Subpopulations Using Cross Center Scrna-Seq Data (2020) (0)
Melanoma and immunotherapy bridge 2015 (2016) (0)
Abstract A005: A phase I study of the safety and immunogenicity of a multipeptide personalized genomic vaccine in the adjuvant treatment of solid cancers (2019) (0)
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
541 mregDC/T helper niches enable local reactivation of CD8 T cells upon PD-1 blockade (2022) (0)
Dynamic changes in serum analyte levels associated with clinical outcome in squamous cell lung cancer trial SWOG Lung-MAP S1400I of nivolumab ± ipilimumab. (2022) (0)
High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. (2022) (0)
Tumors by CD 4 Tumor Antigen for Direct Recognition of Peptide-Selective Presentation of Cytosolic Heat Shock Protein 90-Mediated Old and (2012) (0)
Abstract 439: High Dimensional Single-Cell Immune Contexture of Human Atherosclerotic Plaques and Blood (2017) (0)
Analysis of Spontaneous Vs. Vaccine-Induced Antibody Responses Against Cancer-Testis Antigen MAGE-A3 in Cancer Patients (2011) (0)
Tumor antigen NY-CO-58/KIF2C is strongly overexpressed in a variety of human cancers and evokes spontaneous T cell responses (2008) (0)
Abstract P4-06-01: Human mammary tumor virus, HMTV, is an MMTV-adapted human pathogen (2016) (0)
MAGE-3 Protein in Lung Cancer Patients T Cell Responses to + Vaccine-Induced CD4 (2004) (0)
Poly-ICLC as an adjuvant for NY-ESO-1 protein vaccination with or without Montanide ISA-51 VG in patients with melanoma. (2015) (0)
Naturally occurring immunogenicity of NY-ESO-1 in cancer patients (2003) (0)
Comprehensive approaches to monitor CD8+ T-cell responses against tumor antigen NY-ESO-1 (2003) (0)
690 Correlates of poor response to neoadjuvant anti-PD-1 therapy in hepatocellular carcinoma (HCC) include WNT pathway activation and loss of HLA expression (2022) (0)
In vivo antigen delivery by a Salmonella type III secretion system for therapeutic cancer vaccine (2006) (0)
Long-termComplete Remission Following Radiosurgery and Immunotherapy in aMelanomaPatientwithBrainMetastasis : Immunologic Correlates (2014) (0)
Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (2022) (0)
Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS (2022) (0)
High dimensional profiling of the immune microenvironment in smoldering multiple myeloma (2019) (0)
Germline rare deleterious variant load alters cancer risk, age of onset and tumor characteristics (2021) (0)
Quantitative chest computed tomography combined with plasma cytokines predict outcomes in COVID-19 patients (2022) (0)
Identification of immunogenic markers in pancreatic and ovarian cancer by seromics (2008) (0)
Immunophenotype of regionally recurrent melanoma of the extremity in patients before isolated limb infusion (ILI). (2006) (0)
P3.04-27 An Allogeneic Tumor Cell Lysate Vaccine Induces Immune Responses to Lung Cancer Associated Antigens: Preliminary Results of a Phase II Study (2018) (0)
induce systemic immunity following allogeneic stem cell transplantation Cancer-testis antigens are commonly expressed in multiple myeloma and (2013) (0)
Characterization of Plasma and Immune Cells Molecular Landscape That Play a Role in Rapid Progression of Multiple Myeloma Using Cross Center Scrna-Seq Study (2020) (0)
Abstract 2528: Mapping tumoral and immune heterogeneity in PD-1 responsive glioblastoma (2019) (0)
A5 GM-CSF AUTOANTIBODIES: PREDICTORS OF CROHN’S DISEASE DEVELOPMENT AND A NOVEL THERAPEUTIC APPROACH (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Sacha Gnjatic?

Sacha Gnjatic is affiliated with the following schools:

Sacha Gnjatic's Academic­Influence.com Rankings

Sacha Gnjatic's Degrees

Why Is Sacha Gnjatic Influential?

Sacha Gnjatic's Published Works

Published Works

What Schools Are Affiliated With Sacha Gnjatic?

Sacha Gnjatic's AcademicInfluence.com Rankings